Posts

Standard- and low-dose rivaroxaban in Asians with AF: Effectiveness and Safety

In Asian atrial fibrillation (AF) patients, low-dose rivaroxaban (Xarelto®, Bayer) has a similar effect on the risk of thromboembolism and bleeding but not on myocardial infarction (MI) when compared to the standard-dose, as shown in a retrospective population-based cohort study from Taiwan.